The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Gepotidacin is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing rising drug resistance. Phase 3 trials showed gepotidacin's non-inferiority to nitrofurantoin ...

Blujepa sets itself apart from nitrofurantoin as ... To put it simply, the drug is designed to specifically inhibit bacterial DNA in the E. coli class, which causes the majority of UTI infections ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years ... In these studies, Blujepa was compared with nitrofurantoin, a leading treatment for uncomplicated UTIs.

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years ... In these studies, Blujepa was compared with nitrofurantoin, a leading treatment for uncomplicated UTIs.

In the EAGLE-3 experiment, gepotidacin was statistically superior to nitrofurantoin. “As a first-in-class investigational oral antibiotic with activity against common uropathogens, including ...

47% in patients treated with nitrofurantoin ... the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections ...

The small-molecule drug is the first in a new class of oral antibiotics for uUTIs ... who were randomized to gepotidacin or nitrofurantoin, which inhibits bacterial RNA, DNA and protein synthesis.

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.